The latest update is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ).
Hangzhou Tigermed Consulting Co., Ltd. has announced that its board of directors will meet on April 28, 2025, to review and approve the company’s first quarterly report for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a company based in the People’s Republic of China that operates in the consulting industry, focusing on providing services related to clinical trials and research for the pharmaceutical and biotechnology sectors.
YTD Price Performance: -21.31%
Average Trading Volume: 115
Technical Sentiment Signal: Strong Buy
Current Market Cap: €3.92B
For detailed information about 3347 stock, go to TipRanks’ Stock Analysis page.